CD10 BV421
Clone HI10a (RUO)
- Brand BD Horizon™
- Concentration 6.3 μg/mL
- Vol. Per Test 5 μL
- Isotype Mouse BALB/c IgG1, κ
- Reactivity Human (QC Testing)
- Application
Flow cytometry (Routinely Tested)
- Immunogen Acute CALLA Leukemia Blast Cells
- Workshop No. V CD10.7
- Entrez Gene ID 4311
- Regulatory Status RUO
Regulatory Status Legend
Description
The CD10 antibody, clone HI10a, is derived from the hybridization of mouse P3-63-Ag8.653 myeloma cells with spleen cells of BALB/c mice immunized with blasts from a patient with acute CALLA leukemia.
The CD10 antibody recognizes a 100-kilodalton (kDa) type II transmembrane, glycosylated, zinc-containing metalloprotease. The CD10 antigen is also known as common acute lymphoblastic leukemia antigen (CALLA), neutral endopeptidase (NEP), gp100, and enkephalinase.
Format
BV421 is a polymer-based dye excited by the violet laser and is one of the brightest fluorochromes offered by BD Biosciences. Conjugates are typically 10 times brighter than Pacific Blue™ conjugates and are often as bright as or brighter than PE conjugates. Due to nearly identical excitation and emission properties but different spillover characteristics, BD Horizon BV421, Pacific Blue™, and BD Horizon™ V450 cannot be used simultaneously.
Resources & Tools | ||||||
---|---|---|---|---|---|---|
Spectrum Viewer | Panel Designer | Spectrum Viewer | Download TDS | Regulatory Document Website |
-
Protection of Laboratory Workers from Occupationally Acquired Infections; ApprovedGuideline—Third Edition. Wayne, PA: Clinical and Laboratory Standards Institute; 2005. CLSIdocument M29-A3.
-
Caligaris-Cappio F, Riva M, Tesio L, Schena M, Gaidano G, Bergui L. Human normal CD5+ Blymphocytes can be induced to differentiate to CD5– B lymphocytes with germinal center cell features.Blood. 1989;73:1259-1263.
-
Centers for Disease Control. Perspectives in disease prevention and health promotion update: universalprecautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and otherbloodborne pathogens in health-care settings. MMWR. 1988;37:377-388.
-
Connelly JC, Chambless R, Holiday D, Chittenden K, Johnson AR. Up-regulation of neutralendopeptidase (CALLA) in human neutrophils by granulocyte-macrophage colony-stimulating factor. JLeukoc Biol. 1993;53:685-690.
-
Connelly JC, Skidgel RA, Schulz WW, Johnson AR, Erdos EG. Neutral endopeptidase 24.11 in humanneutrophils: cleavage of chemotactic peptide. Proc Natl Acad Sci USA. 1985;82:8737-8741.
-
Consolini R, Legitimo A, Rondelli R, et al. Clinical relevance of CD10 expression in childhood ALL.Haematologica. 1998;83:967-973.
-
Erdös EG, Skidgel RA. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptidehormones. FASEB J. 1989;3:145-151.
-
Erdös EG, Wagner B, Harbury CB, Painter RG, Skidgel RA, Fa XG. Down-regulation and inactivation ofneutral endopeptidase 24.11 (enkephalinase) in human neutrophils. J Biol Chem.1989;264:14519-14523.
-
Greaves MF. Monoclonal antibodies as probes for leukemic heterogeneity and hematopoieticdifferentiation. In: Knapp W, ed. Leukemia Markers. New York, NY: Academic Press; 1981:19.
-
Hofman P, Selva E, Le Negrate G, et al. CD10 inhibitors increase f-Met-Leu-Phe-induced neutrophiltransmigration. J Leukoc Biol. 1998;63:312-320.
-
LeBien TW, McCormack RT. The common acute lymphoblastic leukemia antigen (CD10)—emancipationfrom a functional enigma. Blood. 1989;73:625-635.
-
Letarte M, Vera S, Tran R, et al. Common acute lymphocytic leukemia antigen is identical to neutralendopeptidase. J Exp Med. 1988;168:1247-1253.
-
Salles G, Rodewald HR, Chin BS, Reinherz EL, Shipp MA. Inhibition of CD10/neutral endopeptidase24.11 promotes B-cell reconstitution and maturation in vivo. Proc Natl Acad Sci USA.1993;90:7618-7622.
-
Zola H. CD10 Workshop Panel report. In: Schlossman SF, Boumsell L, Gilks W, et al, eds. LeucocyteTyping V: White Cell Differentiation Antigens. Vol 1. New York, NY: Oxford University Press;1995:505-507.